Abstract
INTRODUCTION
We investigated the link between habitual caffeine intake with memory impairments and cerebrospinal fluid (CSF) biomarkers in mild cognitive impairment (MCI) and Alzheimer’s disease (AD) patients.
METHODS
MCI (N = 147) and AD (N = 116) patients of the Biomarker of AmyLoid pepTide and AlZheimer’s diseAse Risk (BALTAZAR) cohort reported their caffeine intake at inclusion using a dedicated survey. Associations of caffeine consumption with memory impairments and CSF biomarkers (tau, p-tau181, amyloid beta 1-42 [Aβ1-42], Aβ1-40) were analyzed using logistic and analysis of covariance models.
RESULTS
Adjusted on Apolipoprotein E (APOE ε4), age, sex, education level, and tobacco, lower caffeine consumption was associated with higher risk to be amnestic (OR: 2.49 [95% CI: 1.13 to 5.46]; p = 0.023) and lower CSF Aβ1-42 (p = 0.047), Aβ1-42/Aβ1-40 (p = 0.040), and Aβ1-42/p-tau181 (p = 0.020) in the whole cohort.
DISCUSSION
Data support the beneficial effect of caffeine consumption to memory impairments and CSF amyloid markers in MCI and AD patients.
Highlights

We studied the impact of caffeine consumption in the BALTAZAR cohort.
Low caffeine intake is associated with higher risk of being amnestic in MCI/AD patients.
Caffeine intake is associated with CSF biomarkers in AD patients.


If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: David Blum,
Emeline Cailliau,
Hélène Béhal,
Jean‐Sébastien Vidal,
Constance Delaby,
Luc Buée,
Bernadette Allinquant,
Audrey Gabelle,
Stéphanie Bombois,
Sylvain Lehmann,
Susanna Schraen‐Maschke,
Olivier Hanon,
BALTAZAR study group,
Olivier Hanon,
Frédéric Blanc,
Yasmina Boudali,
Audrey Gabelle,
Jacques Touchon,
Marie‐Laure Seux,
Hermine Lenoir,
Catherine Bayle,
Stéphanie Bombois,
Christine Delmaire,
Xavier Delbeuck,
Florence Moulin,
Emmanuelle Duron,
Florence Latour,
Matthieu Plichart,
Sophie Pichierri,
Galdric Orvoën,
Evelyne Galbrun,
Giovanni Castelnovo,
Lisette Volpe‐Gillot,
Florien Labourée,
Pascaline Cassagnaud,
Claire Paquet,
Françoise Lala,
Bruno Vellas,
Julien Dumurgier,
Anne‐Sophie Rigaud,
Christine Perret‐Guillaume,
Eliana Alonso,
Foucaud du Boisgueheneuc,
Laurence Hugonot‐Diener,
Adeline Rollin‐Sillaire,
Olivier Martinaud,
Clémence Boully,
Yann Spivac,
Agnès Devendeville,
Joël Belmin,
Philippe Robert,
Thierry Dantoine,
Laure Caillard,
David Wallon,
Didier Hannequin,
Nathalie Sastre,
Sophie Haffen,
Anna Kearney‐Schwartz,
Jean‐Luc Novella,
Vincent Deramecourt,
Valérie Chauvire,
Gabiel Abitbol,
Nathalie Schwald,
Caroline Hommet,
François Sellal,
Marie‐Ange Cariot,
Mohamed Abdellaoui,
Sarah Benisty,
Salim Gherabli,
Pierre Anthony,
Frédéric Bloch,
Nathalie Charasz,
Sophie Chauvelier,
Jean‐Yves Gaubert,
Guillaume Sacco,
Olivier Guerin,
Jacques Boddaert,
Marc Paccalin,
Marie‐Anne Mackowiak,
Marie‐Thérèse Rabus,
Valérie Gissot,
Athanase Benetos,
Candice Picard,
Céline Guillemaud,
Gilles Berrut,
Claire Gervais,
Jacques Hugon,
Jean‐Marc Michel,
JeanPhilippe David,
Marion Paulin,
Pierre‐Jean Ousset,
Pierre Vandel,
Sylvie Pariel,
Vincent Camus,
Anne Chawakilian,
Léna Kermanac’h,
Anne‐Cécile Troussiere,
Cécile Adam,
Diane Dupuy,
Elena Paillaud,
Hélène Briault,
Isabelle Saulnier,
Karl Mondon,
Marie‐Agnès Picat,
Marie Laurent,
Olivier Godefroy,
Rezki Daheb,
Stéphanie Libercier,
Djamila Krabchi,
Marie Chupin,
JeanSébastien Vidal,
Edouard Chaussade,
Christiane Baret‐Rose,
Sylvain Lehmann,
Bernadette Allinquant,
Susanna Schraen‐Maschke | August 5, 2024

Wiley: Alzheimer’s & Dementia: Table of Contents